December 19, 2014 / 11:46 PM / 5 years ago

AbbVie says newly approved hepatitis C treatment costs $83,319

Dec 19 (Reuters) - An AbbVie Inc spokeswoman on Friday said that the company’s newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc.

U.S. health regulators earlier on Friday approved AbbVie’s all-oral treatment for hepatitis C, providing the first competition for Gilead. (Reporting by Caroline Humer)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below